In vivo imaging methods, such as PET and MRI, provide sensitive, cost efficient and high-throughput technique for the longitudinal study of tumor models. Many cancers are associated with a high metabolic turnover and PET using the injection of a radiolabeled glucose analogue can be used to quantify the glucose uptake and provide an indication of how aggressive a tumor is. Similarly, this imaging method has proved particularly beneficial in the detection of molecular markers. Combining the metabolic data of PET with the high-resolution anatomical and functional information provided by MRI further improves the analytic capacity.
Bruker offers a full range of preclinical multimodal imaging solutions suited to the study of animal tumor models. The Albira preclinical tri-modal PET/SPECT/CT system as well as the the PET/MR 3T combine multiple modalities in a single, easy-to-use instrument to enable whole-body small rodent scans for the localization and quantification of multi-generational metabolic products and biomarkers